Recent advances in peptide-based therapies for obesity and type 2 diabetes

Jan 6, 2024Peptides

New peptide treatments for obesity and type 2 diabetes

AI simplified

GLP-1 Therapies on OpenScience ↗PubMed ↗DOI ↗

Abstract

In individuals with type 2 diabetes, therapies using incretin-based peptides have achieved reductions in glycated haemoglobin (HbA1c) by > 2% and lowered body weight by > 10%.

Incretin-based therapies have shown reductions in body weight by > 15% in non-diabetic, obese individuals at higher doses.
Emerging evidence indicates potential cardio-protective and reno-protective effects of these therapies.
Other therapies in early development, such as retatrutide and CagriSema, demonstrate strong efficacy.
Adverse gastrointestinal effects associated with incretin therapies are generally mild-to-moderate and transient, but can lead to treatment cessation in some patients.

AI simplified

Options for the treatment of type 2 diabetes mellitus (T2DM) and obesity have recently been expanded by the results of several large clinical trials with incretin-based peptide therapies. Most of these studies have been conducted with the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide, which is available as a once weekly subcutaneous injection and once daily tablet, and the once weekly injected dual agonist tirzepatide, which interacts with receptors for GLP-1 and glucose-dependent insulinotropic polypeptide (GIP). In individuals with T2DM these therapies have achieved reductions of glycated haemoglobin (HbA1c) by > 2% and lowered body weight by > 10%. In some studies, these agents tested in non-diabetic, obese individuals at much higher doses have lowered body weight by > 15%. Emerging evidence suggests these agents can also offer cardio-protective and potentially reno-protective effects. Other incretin-based peptide therapies in early clinical development, notably a triple GLP-1/GIP/glucagon receptor agonist (retatrutide) and a combination of semaglutide with the amylin analogue cagrilintide (CagriSema), have shown strong efficacy. Although incretin therapies can incur adverse gastrointestinal effects these are for most patients mild-to-moderate and transient but result in cessation of treatment in some cases. Thus, the efficacy of new incretin-based peptide therapies is enhancing the opportunity to control body weight and blood glucose and improve the treatment of T2DM and obesity.

Full Text

Full text is available at the source.

View full text (XML) ↗View full text ↗

Recent advances in peptide-based therapies for obesity and type 2 diabetes

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief

Abstract

Full Text

Related papers

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief